BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
TargeGen initiates Phase II clinical trial of topically-applied drug for age-related macular degeneration
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.